Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2021 April;112(2) > Minerva Medica 2021 April;112(2):310-2

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

LETTERS TO THE EDITOR   

Minerva Medica 2021 April;112(2):310-2

DOI: 10.23736/S0026-4806.19.06236-0

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Efficacy and safety of cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with pegylated liposomal doxorubicin±rituximab in treating diffuse large B-cell lymphoma

Yuhuan GAO 1, Yan XIE 2, Lihong LIU 1, Hongwei XUE 3, Ming HOU 4, Mingzhi ZHANG 5, Zeping ZHOU 6, Pengxiang GUO 7, Hongxia YAO 8, Zonghong SHAO 9, Xiaobao XIE 10, Jun ZHU 2

1 Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China; 2 Department of Lymphoma Medicine, Beijing Cancer Hospital, Beijing, China; 3 Department of Oncology, Affiliated Hospital of Medical College of Qingdao University, Qingdao, China; 4 Department of Hematology, Qilu Hospital, Shandong University, Jinan, China; 5 Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 6 Department of Hematology, Second Affiliated Hospital of Kunming Medical University, Kunming, China; 7 Department of Hematology, Guizhou People’s Hospital, Guizhou, China; 8 Department of Hematology, Hainan Provincial People’s Hospital, Hainan, China; 9 Department of Hematology, General Hospital of Tianjin Medical University, Tianjin, China; 10 Department of Hematology, Changzhou First People’s Hospital, Changzhou, China



top of page